Clinical Trial Update: Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial of ibritinib plus rituximab for chronic graft-versus-host disease after allogeneic stem cell transplant was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Chronic Graft-versus-host-disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-11-28